

Selection of Electrical Algorithms to Treat Obesity with Intermittent Vagal Block Using an Implantable Medical Device

DESCRIPTION

Prospective, open-label, multi-center trial	27 subjects <i>n=24 subjects at 6 months</i> 3 centers
6-month follow-up	

RESULTS & SUMMARY

- ⋮ vBloc algorithm durations of 90–150 seconds were associated with greater %EWL
- ⋮ in Phase II clinical trials, and a clinically acceptable safety profile

+ 23% EWL was achieved with a 120-second duration vBloc therapy algorithm

To learn more, visit www.vBloc.com



EnteroMedics, Inc.
2800 Patton Road
St. Paul, MN 55113 USA

TEL: 651.634.3003
FAX: 651.634.3212

The Maestro® Rechargeable System is indicated for use in weight reduction in patients aged 18 years through adulthood who have a Body Mass Index (BMI) of 40 to 45 kg/m², or a BMI of 35 to 39.9 kg/m² with one or more obesity related co-morbid conditions, and have failed at least one supervised weight management program within the past five years. The device should not be implanted in patients with cirrhosis, portal hypertension, esophageal varices or a significant hiatal hernia; patients for whom magnetic resonance imaging (MRI) or diathermy is planned; patients with an implanted electrical medical device or gastrointestinal device or prosthesis.

The most common related adverse events include pain, heartburn, nausea, dysphagia, eructation, and abdominal cramping.

Carefully read the product instruction manuals for complete safety information.

vBloc and Maestro are trademarks of EnteroMedics, Inc.

© 2015 EnteroMedics, Inc. All rights reserved.